Kerstin Albus Selected Research

rociletinib

10/2016

Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR Inhibitors.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Kerstin Albus Research Topics

Disease

5	Neoplasms (Cancer) 10/2016 - 11/2012
4	Lung Neoplasms (Lung Cancer) 11/2015 - 11/2012
1	COVID-19 01/2022
1	Communicable Diseases (Infectious Diseases) 01/2022
1	Infections 01/2021
1	Insulin Resistance 01/2021
1	Adenocarcinoma of Lung 10/2016
1	Small Cell Carcinoma 02/2016
1	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2015
1	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 05/2011
1	Autoimmune Diseases (Autoimmune Disease) 09/2008

Drug/Important Bio-Agent (IBA)

2	Insulin (Novolin)FDA Link 01/2021 - 05/2011
2	Fibroblast Growth Factor Receptors (Fibroblast Growth Factor Receptor)IBA 02/2014 - 11/2012
1	VaccinesIBA 01/2022
1	Glucagon-Like Peptide 1 (GLP 1)IBA 01/2021
1	Glucose (Dextrose)FDA LinkGeneric 01/2021
1	rociletinibIBA 10/2016
1	osimertinibIBA 10/2016
1	Phosphotransferases (Kinase)IBA 11/2015
1	Erlotinib Hydrochloride (CP 358,774)FDA Link 11/2015
1	DNA (Deoxyribonucleic Acid)IBA 07/2015
1	Biological ProductsIBA 01/2015
1	Type 1 Fibroblast Growth Factor Receptor (Fibroblast Growth Factor Receptor 1)IBA 02/2014
1	LigandsIBA 02/2014
1	InsulinsIBA 05/2011
1	Short-Acting InsulinIBA 05/2011
1	Insulin Lispro (Humalog)FDA Link 05/2011
1	Complement Receptors (Complement Receptor)IBA 09/2008

Therapy/Procedure

5	Therapeutics 10/2016 - 11/2012
1	Critical Care (Surgical Intensive Care) 01/2021
1	Aftercare (After-Treatment) 10/2016
1	Genomic Medicine 07/2015